Premium
P3‐001: Nanotechnology‐Based Drug Delivery Systems in Alzheimer's Disease
Author(s) -
Leszek Jerzy W.,
Kurkinen Markku
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1658
Subject(s) - dendrimer , drug delivery , drug , amyloid (mycology) , nanotechnology , blood–brain barrier , bioavailability , alzheimer's disease , disease , in vivo , pharmacology , chemistry , medicine , materials science , neuroscience , biology , biochemistry , central nervous system , microbiology and biotechnology , inorganic chemistry
Background: Conventional drug treatments of Alzheimer’s disease(AD) are ineffective because the therapeutic drugs often have low bioavailability, poor solubility, limited penetration across the blood-brain barrier(BBB). AD is a multi-factorial disease with several pathogenic mechanisms and pathways, therefore multifunctional nanotechnologic treatment methods may be needed to access the many molecular targets in AD.Methods:We have studies the effect of dendrimer’s on the process of brain amyloid formation based on two model peptides derived from the ABeta peptides. Results: We have found that these new polymers have a modulating effect on the process of fibre formation. Depending on their concentration, dendrimers may accelerate or retards the formation of amiloide fibres. This means they are a potentially powerful tool in the design of strategies to manage in vivo amyloid formation. Conclusions: Given their anti-ABeta amyloid properties and their crossing BBB, dendrimers can be potential new agent for early diagnosis and treatment of AD.